Total Payments
$266,341
2024 Payments
$121.81
Companies
6
Transactions
31
Medicare Patients
3,033
Medicare Billing
$487,492
Payment Breakdown by Category
Research$257,765 (96.8%)
Consulting$7,502 (2.8%)
Travel$830.33 (0.3%)
Food & Beverage$243.14 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $257,765 | 9 | 96.8% |
| Consulting Fee | $7,502 | 8 | 2.8% |
| Travel and Lodging | $830.33 | 4 | 0.3% |
| Food and Beverage | $243.14 | 10 | 0.1% |
Payments by Type
Research
$257,765
9 transactions
General
$8,575
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $265,049 | 16 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $907.53 | 10 | $0 (2017) |
| HOYA Medical Singapore PTE LTD | $218.16 | 1 | $0 (2018) |
| Dompe US, Inc. | $121.81 | 1 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $32.16 | 2 | $0 (2019) |
| TISSUETECH, INC. | $11.97 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $121.81 | 1 | Dompe US, Inc. ($121.81) |
| 2021 | $11.97 | 1 | TISSUETECH, INC. ($11.97) |
| 2020 | $40,356 | 4 | Bausch Health US, LLC ($40,356) |
| 2019 | $78,219 | 5 | Bausch Health US, LLC ($78,187) |
| 2018 | $146,724 | 10 | Bausch Health US, LLC ($146,506) |
| 2017 | $907.53 | 10 | Valeant Pharmaceuticals North America LLC ($907.53) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/08/2024 | Dompe US, Inc. | OXERVATE (Drug) | Food and Beverage | In-kind items and services | $121.81 | General |
| Category: SOLUTION/ DROPS | ||||||
| 12/07/2021 | TISSUETECH, INC. | PROKERA (Device), AMNIOGRAFT | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: HUMAN TISSUE PRODUCTS | ||||||
| 07/01/2020 | Bausch Health US, LLC | CVISC50 (Device) | Consulting Fee | Cash or cash equivalent | $43.28 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/30/2020 | Bausch Health US, LLC | CVISC50 (Device) | Consulting Fee | Cash or cash equivalent | $7,200.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/30/2020 | Bausch Health US, LLC | CVISC50 (Device) | — | Cash or cash equivalent | $4,606.20 | Research |
| Study: A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW COHESIVE OVD WHEN COMPARED TO A CONTROL OVD • Category: OPHTHALMOLOGY | ||||||
| 03/31/2020 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $28,507.00 | Research |
| Study: A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW COHESIVE OVD WHEN COMPARED TO A CONTROL OVD | ||||||
| 07/29/2019 | Bausch Health US, LLC | DVISC40 (Device) | — | Cash or cash equivalent | $31,539.15 | Research |
| Study: BAUSCH & LOMB OVD DISPERSIVE DVISC40 STUDY S877 • Category: OPHTHALMOLOGY | ||||||
| 06/04/2019 | Novartis Pharmaceuticals Corporation | DUREZOL (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/17/2019 | Bausch Health US, LLC | DVISC40 (Device) | — | Cash or cash equivalent | $8,782.20 | Research |
| Study: BAUSCH & LOMB OVD DISPERSIVE DVISC40 STUDY S877 • Category: OPHTHALMOLOGY | ||||||
| 03/12/2019 | Novartis Pharmaceuticals Corporation | DUREZOL (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/06/2019 | Bausch Health US, LLC | DVISC40 (Device) | — | Cash or cash equivalent | $37,865.80 | Research |
| Study: BAUSCH & LOMB OVD DISPERSIVE DVISC40 STUDY S877 • Category: OPHTHALMOLOGY | ||||||
| 11/01/2018 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $23.50 | General |
| 10/23/2018 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $88,638.00 | Research |
| Study: A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW OPHTHALMIC VISCOSURGICAL DEVICE OVD WHEN COMPARED TO A CONTROL OVD | ||||||
| 09/18/2018 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $47.00 | General |
| 09/18/2018 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $23.50 | General |
| 08/27/2018 | HOYA Medical Singapore PTE LTD | — | — | In-kind items and services | $218.16 | Research |
| Study: MOON Study • Category: Ophthalmology | ||||||
| 05/23/2018 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $53,052.85 | Research |
| Study: A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW OPHTHALMIC VISCOSURGICAL DEVICE OVD WHEN COMPARED TO A CONTROL OVD | ||||||
| 05/23/2018 | Bausch Health US, LLC | — | — | Cash or cash equivalent | $4,556.00 | Research |
| Study: A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW OPHTHALMIC VISCOSURGICAL DEVICE OVD WHEN COMPARED TO A CONTROL OVD | ||||||
| 05/10/2018 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $15.00 | General |
| 05/08/2018 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $102.65 | General |
| 05/02/2018 | Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $47.00 | General |
| 10/28/2017 | Valeant Pharmaceuticals North America LLC | DVISC40 (Device) | Travel and Lodging | Cash or cash equivalent | $362.33 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/28/2017 | Valeant Pharmaceuticals North America LLC | DVISC40 (Device) | Travel and Lodging | Cash or cash equivalent | $220.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/28/2017 | Valeant Pharmaceuticals North America LLC | DVISC40 (Device) | Travel and Lodging | Cash or cash equivalent | $213.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/28/2017 | Valeant Pharmaceuticals North America LLC | DVISC40 (Device) | Food and Beverage | In-kind items and services | $53.00 | General |
| Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW OPHTHALMIC VISCOSURGICAL DEVICE OVD WHEN COMPARED TO A CONTROL OVD | Bausch Health US, LLC | $146,247 | 3 |
| BAUSCH & LOMB OVD DISPERSIVE DVISC40 STUDY S877 | Bausch Health US, LLC | $78,187 | 3 |
| A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW COHESIVE OVD WHEN COMPARED TO A CONTROL OVD | Bausch Health US, LLC | $33,113 | 2 |
| MOON Study | HOYA Medical Singapore PTE LTD | $218.16 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 600 | 940 | $237,620 | $103,537 |
| 2022 | 11 | 792 | 1,257 | $257,918 | $142,476 |
| 2021 | 12 | 846 | 1,217 | $184,258 | $131,787 |
| 2020 | 11 | 795 | 1,150 | $159,755 | $109,691 |
Total Patients
3,033
Total Services
4,564
Medicare Billing
$487,492
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 390 | 680 | $132,197 | $58,271 | 44.1% |
| 65756 | Transplantation of outer layer of corneal tissue | Facility | 2023 | 15 | 16 | $30,703 | $14,564 | 47.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 109 | 109 | $26,758 | $11,071 | 41.4% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 21 | 27 | $24,614 | $10,235 | 41.6% |
| 68761 | Closure of tear duct opening using plug | Office | 2023 | 31 | 68 | $14,673 | $5,491 | 37.4% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Facility | 2023 | 11 | 12 | $6,339 | $3,067 | 48.4% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 23 | 28 | $2,335 | $837.73 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 419 | 806 | $128,960 | $74,354 | 57.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 154 | 154 | $31,878 | $17,623 | 55.3% |
| 65756 | Transplantation of outer layer of corneal tissue | Facility | 2022 | 13 | 14 | $20,132 | $12,597 | 62.6% |
| 68761 | Closure of tear duct opening using plug | Office | 2022 | 62 | 120 | $23,244 | $10,644 | 45.8% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Facility | 2022 | 35 | 43 | $18,670 | $10,417 | 55.8% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2022 | 18 | 20 | $16,950 | $8,074 | 47.6% |
| 65400 | Removal of growth of cornea | Facility | 2022 | 11 | 12 | $10,224 | $5,503 | 53.8% |
| 65800 | Removal of eye fluid | Office | 2022 | 13 | 15 | $2,220 | $1,358 | 61.2% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2022 | 31 | 35 | $2,620 | $1,150 | 43.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 25 | $2,825 | $638.93 | 22.6% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2022 | 13 | 13 | $195.00 | $118.49 | 60.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 357 | 601 | $51,277 | $34,246 | 66.8% |
| 66984 | Removal of cataract with insertion of lens, simple | Facility | 2021 | 35 | 51 | $28,599 | $20,934 | 73.2% |
| 65756 | Transplant of outer layer of corneal tissue | Facility | 2021 | 16 | 17 | $19,573 | $15,847 | 81.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 115 | 148 | $18,584 | $13,403 | 72.1% |
| 68761 | Closure of tear duct opening using plug | Office | 2021 | 80 | 136 | $17,651 | $11,621 | 65.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 77 | 77 | $12,701 | $9,079 | 71.5% |
| 66982 | Removal of cataract with insertion of lens, complex | Facility | 2021 | 11 | 12 | $8,952 | $6,802 | 76.0% |
About Dr. Jung Dao, MD
Dr. Jung Dao, MD is a Ophthalmology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427007202.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jung Dao, MD has received a total of $266,341 in payments from pharmaceutical and medical device companies, with $121.81 received in 2024. These payments were reported across 31 transactions from 6 companies. The most common payment nature is "" ($257,765).
As a Medicare-enrolled provider, Dao has provided services to 3,033 Medicare beneficiaries, totaling 4,564 services with total Medicare billing of $487,492. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Phoenix, AZ
- Active Since 05/09/2006
- Last Updated 05/15/2012
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1427007202
Products in Payments
- DVISC40 (Device) $79,095
- CVISC50 (Device) $11,849
- OXERVATE (Drug) $121.81
- DUREZOL (Drug) $32.16
- PROKERA (Device) $11.97
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Phoenix
Dr. Jordan Graff, Md, MD
Ophthalmology — Payments: $413,274
Ophthalmology $413,274
Dr. Christopher Fecarotta, Md, MD
Ophthalmology — Payments: $374,240
Ophthalmology $374,240
Dr. Pravin Dugel
Ophthalmology — Payments: $366,469
Ophthalmology $366,469
Benjamin Bakall, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $130,789
Ophthalmology $130,789
Jaime Gaitan, Md, MD
Ophthalmology — Payments: $127,271
Ophthalmology $127,271
Dr. Christine Funke, Md, MD
Ophthalmology — Payments: $113,633
Ophthalmology $113,633